医学
抗体
免疫学
抗体效价
神经嵴
效价
抗体反应
疾病
通气不足
先天性中枢性低通气综合征
内科学
儿科
特异性抗体
静脉注射免疫球蛋白
作者
Akari Nakamura‐Utsunomiya,Kosei Hasegawa,Taisuke Ono,Junko Kanno,Hirohito Shima,Yuichi Suzuki,Manabu Tanaka,Kento Ikegawa,Naoko Amano,Yukiko Mogami,Yuki Yamada,Natsuko Futagawa,Yousuke Higuchi,Daiki Sasaoka,Fusa Nagamatsu,Jun Mori,Masanobu Kawai,Hiroshi Moritake,Masanori Nishi,Muneaki Matsuo
标识
DOI:10.1210/clinem/dgag109
摘要
CONTEXT: The early diagnosis of ROHHAD (-NET) syndrome is hard for pediatricians and endocrinologists because some symptoms, including rapid-onset obesity and autonomic dysfunction, are nonspecific and detected progressively. An autoimmune mechanism involving ZSCAN1 antibody is proposed to contribute to the pathogenesis of the disease. However, the clinical significance of the anti-ZSCAN1 antibody titer remains unestablished. OBJECTIVE: This work aims to clarify the clinical features at onset or first visit to hospitals and the significance of anti-ZSCAN1 and anti-Nax antibody titers by enzyme-linked immunosorbent assay in patient serum. METHODS: An observational cohort study was conducted of patients diagnosed clinically with ROHHAD (-NET) syndrome in Japan. RESULTS: Obesity was observed in 72.7% of cases, while autonomic dysregulation and central hypoventilation were observed in 18.2% and 36.2% of cases, respectively. Serum prolactin levels measured at the initial consultation were significantly elevated in all cases. Antibody analyses revealed positivity in 70% of 30 cases. The anti-ZSCAN1 antibody titer associated with neural crest tumors (NCTs) was significantly higher than that without tumors. In a patient with NCT, the trend of anti-ZSCAN1 antibody titer tended to be decreased after tumor resection or immunosuppressive therapy. CONCLUSION: This study suggests that we need to evaluate clinically and in detail the autonomic dysregulation and hypoventilation to diagnose ROHHAD (-NET) syndrome in its early stages. Additionally, anti-ZSCAN1 antibody titers reflect the association of NCTs and may serve as a potential marker for the efficacy of tumor therapy. We also propose the anti-ZSCAN1 antibody titer as an indicator for the clinical management of ROHHAD (-NET) syndrome.
科研通智能强力驱动
Strongly Powered by AbleSci AI